Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
1
|
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
|
N Engl J Med
|
2009
|
5.79
|
2
|
Dendritic cell immunotherapy: mapping the way.
|
Nat Med
|
2004
|
4.28
|
3
|
CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis.
|
Arthritis Rheum
|
2003
|
2.68
|
4
|
Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
|
Clin Cancer Res
|
2008
|
2.06
|
5
|
Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.
|
Clin Cancer Res
|
2009
|
2.04
|
6
|
MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways.
|
Traffic
|
2009
|
1.98
|
7
|
High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer.
|
Cancer Res
|
2007
|
1.96
|
8
|
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
|
J Immunol
|
2002
|
1.93
|
9
|
Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.
|
Cancer Res
|
2004
|
1.90
|
10
|
Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy.
|
J Invest Dermatol
|
2011
|
1.71
|
11
|
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.
|
Proc Natl Acad Sci U S A
|
2010
|
1.67
|
12
|
Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo.
|
J Immunol
|
2002
|
1.66
|
13
|
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
|
Clin Cancer Res
|
2008
|
1.66
|
14
|
Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm.
|
Cancer Res
|
2010
|
1.59
|
15
|
Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.
|
J Invest Dermatol
|
2009
|
1.56
|
16
|
CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity.
|
J Immunol
|
2007
|
1.54
|
17
|
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens.
|
Proc Natl Acad Sci U S A
|
2007
|
1.53
|
18
|
Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas.
|
J Immunol
|
2002
|
1.46
|
19
|
Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
|
Cancer Res
|
2003
|
1.40
|
20
|
Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
|
Clin Cancer Res
|
2011
|
1.39
|
21
|
Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization.
|
Clin Cancer Res
|
2005
|
1.38
|
22
|
CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.
|
Proc Natl Acad Sci U S A
|
2002
|
1.34
|
23
|
Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment.
|
Clin Cancer Res
|
2005
|
1.30
|
24
|
Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
|
J Immunol
|
2004
|
1.29
|
25
|
Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells.
|
J Exp Med
|
2007
|
1.28
|
26
|
Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.
|
Eur J Immunol
|
2010
|
1.27
|
27
|
Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer.
|
Clin Cancer Res
|
2009
|
1.27
|
28
|
Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes.
|
PLoS One
|
2011
|
1.26
|
29
|
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes.
|
Nat Immunol
|
2010
|
1.24
|
30
|
Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells.
|
J Biol Chem
|
2007
|
1.23
|
31
|
Therapeutic cancer vaccines.
|
J Clin Invest
|
2015
|
1.23
|
32
|
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer.
|
J Transl Med
|
2012
|
1.23
|
33
|
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
|
Mol Immunol
|
2008
|
1.23
|
34
|
Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects.
|
Cancer Res
|
2002
|
1.22
|
35
|
Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine.
|
J Immunol
|
2006
|
1.19
|
36
|
Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.
|
Clin Cancer Res
|
2013
|
1.18
|
37
|
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.
|
Nat Med
|
2006
|
1.17
|
38
|
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors.
|
PLoS One
|
2011
|
1.16
|
39
|
Ins and outs of dendritic cells.
|
Int Arch Allergy Immunol
|
2006
|
1.16
|
40
|
Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation.
|
Eur J Immunol
|
2008
|
1.16
|
41
|
Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response.
|
PLoS Pathog
|
2013
|
1.15
|
42
|
Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors.
|
J Immunol
|
2012
|
1.14
|
43
|
Design and development of synthetic peptide vaccines: past, present and future.
|
Expert Rev Vaccines
|
2007
|
1.14
|
44
|
Vaccination for treatment and prevention of cancer in animal models.
|
Adv Immunol
|
2006
|
1.11
|
45
|
Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen.
|
Cancer Res
|
2008
|
1.11
|
46
|
Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element.
|
Int J Cancer
|
2008
|
1.11
|
47
|
The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment.
|
J Immunol
|
2004
|
1.10
|
48
|
Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition.
|
J Pathol
|
2009
|
1.09
|
49
|
Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells.
|
J Immunol
|
2005
|
1.09
|
50
|
Therapeutic vaccination against human papilloma virus induced malignancies.
|
Curr Opin Immunol
|
2011
|
1.08
|
51
|
Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides.
|
Hum Immunol
|
2003
|
1.07
|
52
|
Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.
|
Clin Cancer Res
|
2006
|
1.06
|
53
|
Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease.
|
Int J Cancer
|
2006
|
1.05
|
54
|
Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques.
|
AIDS
|
2012
|
1.02
|
55
|
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.
|
J Transl Med
|
2013
|
1.02
|
56
|
C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L.
|
Nat Chem Biol
|
2005
|
1.01
|
57
|
Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen.
|
Cancer Res
|
2008
|
0.99
|
58
|
Human CD4+ T cells stimulated by conserved adenovirus 5 hexon peptides recognize cells infected with different species of human adenovirus.
|
Eur J Immunol
|
2006
|
0.99
|
59
|
The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors.
|
Int J Cancer
|
2010
|
0.98
|
60
|
A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.
|
Cancer Immunol Immunother
|
2012
|
0.97
|
61
|
Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy.
|
Adv Drug Deliv Rev
|
2006
|
0.96
|
62
|
Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer.
|
Semin Immunol
|
2013
|
0.96
|
63
|
Macrophages are vital in spontaneous intraocular tumor eradication.
|
Invest Ophthalmol Vis Sci
|
2006
|
0.94
|
64
|
Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia.
|
Int J Cancer
|
2006
|
0.94
|
65
|
Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation.
|
Eur J Immunol
|
2013
|
0.93
|
66
|
Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates CD8+ central memory-like T cells that can be rescued for full effector function.
|
J Immunol
|
2005
|
0.93
|
67
|
T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
|
Clin Cancer Res
|
2011
|
0.92
|
68
|
Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists.
|
Vaccine
|
2006
|
0.92
|
69
|
Colorectal cancer vaccines in clinical trials.
|
Expert Rev Vaccines
|
2011
|
0.92
|
70
|
Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire.
|
Cancer Res
|
2005
|
0.92
|
71
|
CD27-CD70 costimulation controls T cell immunity during acute and persistent cytomegalovirus infection.
|
J Virol
|
2013
|
0.91
|
72
|
Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells.
|
J Immunol
|
2012
|
0.91
|
73
|
Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways.
|
Clin Cancer Res
|
2007
|
0.90
|
74
|
SPI-CI and SPI-6 cooperate in the protection from effector cell-mediated cytotoxicity.
|
Blood
|
2004
|
0.90
|
75
|
Immunotherapy for persistent viral infections and associated disease.
|
Trends Immunol
|
2011
|
0.90
|
76
|
Prediction of the immunogenic potential of frameshift-mutated antigens in microsatellite instable cancer.
|
Int J Cancer
|
2008
|
0.89
|
77
|
The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study.
|
Cancer Immunol Immunother
|
2013
|
0.89
|
78
|
Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment.
|
Int J Cancer
|
2012
|
0.89
|
79
|
CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
|
Cancer Res
|
2005
|
0.89
|
80
|
2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation.
|
Bioorg Med Chem Lett
|
2009
|
0.89
|
81
|
The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools.
|
Cancer Immunol Immunother
|
2012
|
0.88
|
82
|
Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer.
|
Int J Cancer
|
2005
|
0.88
|
83
|
Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.
|
Cancer Res
|
2002
|
0.88
|
84
|
Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.
|
PLoS One
|
2010
|
0.88
|
85
|
Characterization of antigen-specific immune responses induced by canarypox virus vaccines.
|
J Immunol
|
2007
|
0.88
|
86
|
Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial.
|
Int J Cancer
|
2012
|
0.88
|
87
|
Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.
|
PLoS One
|
2012
|
0.87
|
88
|
Cancer immunology.
|
Curr Opin Immunol
|
2011
|
0.87
|
89
|
In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway.
|
J Immunol
|
2002
|
0.87
|
90
|
Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.
|
Clin Cancer Res
|
2002
|
0.86
|
91
|
Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia.
|
Int J Cancer
|
2008
|
0.85
|
92
|
Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction.
|
J Immunol
|
2004
|
0.84
|
93
|
Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients.
|
Cancer Gene Ther
|
2003
|
0.84
|
94
|
Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-Specific CD4+ memory T cell responses.
|
J Infect Dis
|
2010
|
0.84
|
95
|
Circulating specific antibodies enhance systemic cross-priming by delivery of complexed antigen to dendritic cells in vivo.
|
Eur J Immunol
|
2012
|
0.84
|
96
|
N-tetradecylcarbamyl lipopeptides as novel agonists for Toll-like receptor 2.
|
J Med Chem
|
2014
|
0.84
|
97
|
Experience with synthetic vaccines for cancer and persistent virus infections in nonhuman primates and patients.
|
Adv Immunol
|
2012
|
0.84
|
98
|
Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells.
|
Mol Immunol
|
2008
|
0.83
|
99
|
DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge.
|
AIDS
|
2013
|
0.83
|
100
|
CD8 T-cell recognition of human 5T4 oncofetal antigen.
|
Int J Cancer
|
2006
|
0.83
|
101
|
Cancer: immune pact with the enemy.
|
Nature
|
2007
|
0.83
|
102
|
The distinct role of T cell costimulation in antiviral immunity.
|
Curr Opin Virol
|
2013
|
0.82
|
103
|
Maintenance of immune tolerance depends on normal tissue homeostasis.
|
J Immunol
|
2005
|
0.82
|
104
|
The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development.
|
Virus Res
|
2002
|
0.82
|
105
|
Cancer immunology: cat and mouse games.
|
Nature
|
2005
|
0.81
|
106
|
Recombinant adenovirus-transduced human dendritic cells engineered to secrete interleukin-10 (IL-10) suppress Th1-type responses while selectively activating IL-10-producing CD4+ T cells.
|
Hum Immunol
|
2004
|
0.81
|
107
|
The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy.
|
Anticancer Agents Med Chem
|
2014
|
0.81
|
108
|
Magnitude and polarization of P53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors.
|
Int J Cancer
|
2003
|
0.80
|
109
|
Competition-based cellular peptide binding assay for HLA class I.
|
Curr Protoc Immunol
|
2004
|
0.80
|
110
|
Effective CD8(+) T cell priming and tumor protection by enterotoxin B subunit-conjugated peptides targeted to dendritic cells.
|
Vaccine
|
2009
|
0.80
|
111
|
Mutation-specific T cells for immunotherapy of gliomas.
|
N Engl J Med
|
2015
|
0.80
|
112
|
Synthesis of 2-alkoxy-8-hydroxyadenylpeptides: towards synthetic epitope-based vaccines.
|
Bioorg Med Chem Lett
|
2006
|
0.79
|
113
|
Antigen-specific active immunotherapy for ovarian cancer.
|
Cochrane Database Syst Rev
|
2014
|
0.79
|
114
|
Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope.
|
J Immunother
|
2002
|
0.79
|
115
|
Revival of the regulatory T cell: new targets for drug development.
|
Drug Discov Today
|
2004
|
0.77
|
116
|
DC-induced CD8(+) T-cell response is inhibited by MHC class II-dependent DX5(+)CD4(+) Treg.
|
Eur J Immunol
|
2009
|
0.77
|
117
|
Structured reporting of T cell assay results.
|
Cancer Immun
|
2013
|
0.77
|
118
|
Escort service for cross-priming.
|
Nat Immunol
|
2005
|
0.76
|
119
|
Conference scene: Immune signatures in the tumor and beyond.
|
Immunotherapy
|
2012
|
0.75
|
120
|
Safety in numbers.
|
Eur J Hum Genet
|
2005
|
0.75
|
121
|
Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model.
|
Vaccine
|
2004
|
0.75
|
122
|
Immunotherapy of cancer through targeting of the p53 tumor antigen.
|
Arch Immunol Ther Exp (Warsz)
|
2002
|
0.75
|